Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.63 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.49 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.49 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7320298 | 0.87 | TLR8 (0.53) | ARTLR8MAPK1L3MBTL1KCNMA1 | |
| SCHEMBL17840412 | 0.85 | TLR8 (0.65) | ARTLR8TLR9TLR7 | |
| SCHEMBL17840411 | 0.85 | TLR8 (0.65) | ARTLR8TLR9TLR7 | |
| SCHEMBL19957396 | 0.84 | TLR8 (0.53) | ARTLR8MAPTALDH1A1KDM4E | |
| SCHEMBL23369715 | 0.83 | TLR8 (0.52) | ARTLR8MAPTSMN1; SMN2TNNI3 | |
| SCHEMBL18980105 | 0.82 | TLR8 (0.53) | ARTLR8KDM4EHRH1HRH3 | |
| SCHEMBL4879640 | 0.81 | AR (0.53) | ARTLR8MAPTSMN1; SMN2TNNI3 | |
| SCHEMBL18980772 | 0.81 | TLR8 (0.50) | ARTLR8KDM4EKCNMA1TLR9 | |
| SCHEMBL21795382 | 0.80 | TLR8 (0.54) | ARTLR8KDM4EHRH1HRH3 | |
| SCHEMBL21795290 | 0.80 | TLR8 (0.54) | ARTLR8KDM4ETLR9TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756101-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | Acadia Pharmaceuticals Inc. (US) | 2007-02-28 | — | — | EP | claimed |
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2006-01-19 | — | — | US | claimed |
| WO-2005115361-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | ACADIA PHARMACEUTICALS INC. (US) | 2005-12-08 | — | — | WO | claimed |
| US-4933447-A | FOR TREATMENT OF CARDIOVASCULAR DISORDERS | SS PHARMACEUTICAL CO., LTD. (JP) | 1990-06-12 | — | — | US | claimed |
| US-20080009489-A1 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | ACADIAN PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-7268232-B2 | Androgen receptor modulators and method of treating disease using the same | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1756101-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | Acadia Pharmaceuticals Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20070004679-A1 | Androgen receptor modulators and methods of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2007-01-04 | — | — | US | disclosed |
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005115361-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | ACADIA PHARMACEUTICALS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-4933447-A | FOR TREATMENT OF CARDIOVASCULAR DISORDERS | SS PHARMACEUTICAL CO., LTD. (JP) | 1990-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | NR5A1, AR, CYP17A1 | AR 2/4885TLR8 1728/4885MAPT 3702/4885 |
| US-20070004679-A1 | Androgen receptor modulators and methods of treating disease using the same | NR5A1, AR, ESRRA | AR 2/4885TLR8 1873/4885MAPT 3809/4885 |
| US-20080009489-A1 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | NR5A1, AR, CYP17A1 | AR 2/4885TLR8 1728/4885MAPT 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.